CAG
PRQR icon

Csenge Advisory Group’s ProQR Therapeutics PRQR Stock Holding History

Csenge Advisory Group’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,000
Closed -$18.5K – 746
2024
Q3 		$18.5K Hold
10,000
– – ﹤0.01% 701
2024
Q2 		$16.6K Hold
10,000
– – ﹤0.01% 655
2024
Q1 		$22.9K Hold
10,000
– – ﹤0.01% 701
2023
Q4 		$19.8K Hold
10,000
– – ﹤0.01% 656
2023
Q3 		$13K Hold
10,000
– – ﹤0.01% 633
2023
Q2 		$16.2K Hold
10,000
– – ﹤0.01% 655
2023
Q1 		$21.3K Hold
10,000
– – ﹤0.01% 588
2022
Q4 		$37K Hold
10,000
– – ﹤0.01% 585
2022
Q3 		$7K Buy
+10,000
New +$8.03K ﹤0.01% 608

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Csenge Advisory Group's PRQR Position: Q4 2024 in Review

Csenge Advisory Group sold out of ProQR Therapeutics (PRQR) in Q4 2024, closing a stake of 10,000 shares — an estimated $18.5K sold.

Csenge Advisory Group first reported a position in PRQR in Q3 2022 and held it in 9 quarters. The position peaked at $37K in Q4 2022. 77 funds tracked by Wall St. Rank hold PRQR as of Q4 2024.

  • Csenge Advisory Group reported no remaining ProQR Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Csenge Advisory Group sold 10,000 ProQR Therapeutics shares in Q4 2024, an estimated $18.5K.
  • Csenge Advisory Group first reported a position in ProQR Therapeutics in Q3 2022 and held it in 9 quarters.
  • Csenge Advisory Group's ProQR Therapeutics position peaked at $37K in Q4 2022.
  • 77 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q4 2024.

Based on Csenge Advisory Group's 13F filing for Q4 2024, filed 30 Jan 2025.